SLC38A2 antibody (Intracellular)

Catalog No. ABIN7581976

This Rabbit Polyclonal antibody specifically detects SLC38A2 in WB and IHC. It exhibits reactivity toward Mouse.

Quick Overview for SLC38A2 antibody (Intracellular) (ABIN7581976)

Target: SLC38A2 (Solute Carrier Family 38, Member 2 (SLC38A2))

Reactivity: Mouse

Host: Rabbit

Clonality: Polyclonal

Conjugate: This SLC38A2 antibody is un-conjugated

Application: Western Blotting (WB), Immunohistochemistry (IHC)

Product Details anti-SLC38A2 Antibody

Binding Specificity: AA 25-40, Intracellular

Purpose: A Rabbit Polyclonal antibody to SLC38A2 (SNAT2) Transporter

Sequence: (C)DFNYSYPTKQ AALKSH

Specificity: Intracellular, N-terminus.

Predicted Reactivity: Human,rat- identical

Characteristics: Anti-SLC38A2 (SNAT2) Antibody (ABIN7581976) is a highly specific antibody directed against an epitope of the mouse protein. The antibody can be used in western blot and immunohistochemistry applications. It has been designed to recognize SNAT2 from rat, mouse and human samples.

Purification: Affinity purified on immobilized antigen.

Immunogen: (C)DFNYSYPTKQAALKSH, corresponding to amino acid residues 25 - 40 of mouse SLC38A2

Isotype: IgG

Application Details

Application Notes:

Antigen preadsorption control: 1 μg peptide per 1 μg antibody

Application Dilutions Immunohistochemistry paraffin embedded sections ihc: 1:300

Application Dilutions Western blot wb: 1:400

Restrictions: For Research Use only

Handling

Format: Lyophilized

Reconstitution: 0.2 mL double distilled water (DDW).

Concentration: 1 mg/mL

Buffer: PBS pH 7.4

Storage: 4 °C,-20 °C

Storage Comment:

Storage before reconstitution: The antibody ships as a lyophilized powder at room temperature. Upon arrival, it should be stored at -20°C.

Storage after reconstitution: The reconstituted solution can be stored at 4°C for up to 1 week. For longer periods, small aliquots should be stored at -20°C. Avoid multiple freezing and thawing. Centrifuge all antibody preparations before use (10000 x g 5 min).

Target Details for SLC38A2

Target: SLC38A2 (Solute Carrier Family 38, Member 2 (SLC38A2))

Alternative Name: SLC38A2

Background: Solute Carrier Family 38 Member 2, Sodium-Coupled Neutral Amino Acid Transporter 2, System A Amino Acid Transporter 2, System N Amino Acid Transporter 2, SAT2,Solute carrier family 38 member 2, SLC38A2, also known as sodium-coupled neutral amino acid symporter 2, system A amino acid transporter 2 (ATA2), and system N amino acid transporter 2 (SNAT2), is a cotransporting symporter of neutral amino acids and sodium ions across the cell membrane with a 1:1 stoichiometry.1,2The mechanism of transport of SLC38A2 is pH -sensitive, Na+ dependent, Li+-intolerant, and exhibits specificity for short-chain neutral amino acids. SLC38A2 is composed of 506 amino acids and possesses 11 transmembrane domains with an intracellular N terminus and an extracellular C-terminus, as indicated by hydropathy analysis. Competition experiments demonstrate that human SLC38A2 recognizes multiple neutral amino acids as substrates, including alanine, glycine, serine, proline, methionine, asparagine, glutamine, threonine, and leucine. Since the transport of each neutral amino acid into the cell results in the net movement of one positive charge, the process is electrogenic. SLC38A2 also modulates a leak anion current, which is mediated by the binding of Na+, can be inhibited to different extents by substrate transport, and is thermodynamically uncoupled from Na+ and substrate transport.1,3As demonstrated by Northern blot analyses, human tissue distribution of SLC38A2 mRNA is ubiquitous and has been identified in brain, colon, heart, kidney, liver, lung, muscle, placenta, small intestine, spleen, stomach, and testis.1 SLC38A2 has been implicated in the pathophysiology of various medical conditions, such as cancer, neurological diseases, and diabetes mellitus. SLC38A2-dependent osmoadaptation has been implicated in heart failure, central pontine myelinolysis, and dry eye syndrome.SLC38A2 is believed to participate in the transport of glutamine from astrocytes to neurons through the glutamate-glutamine cycle.2Slc38a2 contributes to the pathology in a number of diseases such as cancer, epilepsy and diabetes mellitus.2,3,4Several studies have suggested that SLC38A2/SNAT2 plays a significant role in cancer by affecting the nutrient supply to cancer cells. Cancer cells have a high demand for amino acids to support their rapid growth and proliferation. SNAT2 facilitates the transport of amino acids, such as glutamine and leucine, into cancer cells. These amino acids are crucial for energy production, protein synthesis, and other metabolic processes necessary for tumor growth.4Additionally, SLC38A2/SNAT2 has been linked to the mTOR (mammalian target of rapamycin) signalling pathway, a key regulator of cell growth and metabolism. Activation of mTOR signalling is commonly observed in cancer cells and contributes to their uncontrolled growth. SNAT2-mediated amino acid transport is thought to influence mTOR activity, potentially promoting cancer cell survival and proliferation.4,5Moreover, the expression of SLC38A2/SNAT2 has been found to be dysregulated in various cancer types. Increased expression of SNAT2 has been observed in some tumors, and this overexpression is often associated with poor prognosis and aggressive tumor behaviour. In contrast, reduced expression of SNAT2 has been reported in other cancers.5-7Due to its potential importance in cancer progression, SLC38A2/SNAT2 has garnered attention as a potential therapeutic target. Inhibiting SNAT2-mediated amino acid transport could be explored as a strategy to hinder cancer cell growth and sensitize tumors to existing treatments.5-7

Gene ID: 67760

UniProt: Q8CFE6

Pathways: Dicarboxylic Acid Transport